Characteristics of the studies included in the meta-analysis
| Studyreference | Publication year | Jadad score (/5) | Number of patients | Follow-up duration (years) | bDMARD | Mean MTX dose (mg/week) |
|---|---|---|---|---|---|---|
| 1. ACCOMPANY27 | 2013 | 3 | 100 | 0.33 | Abatacept | 16.2 |
| 2. AVERT18 | 2015 | 4 | 235 | 1.00 | Abatacept | 15–20* |
| 3. PREMIER15 | 2006 | 4 | 542 | 2.00 | Adalimumab | 20 |
| 4. ADORE30 | 2006 | 2 | 314 | 0.31 | Etanercept | ≥15 |
| 5. COMET17 | 2010 | 5 | 312 | 1.00 | Etanercept | 17 |
| 6. Iannone21 | 2014 | 3 | 20 | 1.04 | Etanercept | 10 |
| 7. JESMR22 | 2011 | 2 | 147 | 1.00 | Etanercept | 7 |
| 8. TEMPO29 | 2006 | 4 | 454 | 3.00 | Etanercept | 16.4 |
| 9. GO-BEFORE17 | 2013 | 5 | 637 | 2.00 | Golimumab | 19.15 |
| 10. GO-FORWARD24 | 2013 | 5 | 444 | 2.00 | Golimumab | 15–25 |
| 11. Taylor28 | 2011 | 4 | 514 | 0.92 | Golimumab | 15–25 |
| 12. Maini25 | 1998 | 2 | 87 | 0.50 | Infliximab | 7.5 |
| 13. Edwards16 | 2004 | 4 | 80 | 0.92 | Rituximab | ≥10 |
| 14. ACT-RAY20 | 2014 | 5 | 553 | 2.00 | Tocilizumab | ≥15 |
| 15. CHARISMA26 | 2006 | 5 | 310 | 0.38 | Tocilizumab | 10–25 |
| 16. SURPRISE23 | 2016 | 3 | 226 | 1.00 | Tocilizumab | 8 |
*Possibility of changing to a dose <10 mg/week in the case of intolerance.
bDMARDs, biologic disease-modifying antirheumatic drugs; MTX, methotrexate.